All pharmaceutical companies selling drugs in the US must be partially compliant with the FDA serialisation regulations since January 2015. And since the beginning of...

Eslicarbazepine acetate was shown not to have a significant negative consequence on attention, information processing and working memory; in addition it was shown to ...

Genkyotex, a biopharmaceutical company and the leader in NOX therapies, announced today that it has begun enrolling patients into the Company's Phase 2 clinical trial...

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is delighted to an...

The uptake of mobile health (mHealth), which is used worldwide to deliver a range of healthcare services, including data collection and remote patient monitoring, wil...

EYSINS, Switzerland and RARITAN, N.J. – Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, and Ortho Clinical Diagnostics (“Ortho”), a global lea...

Although the liver cancer space currently lacks marketed treatments, with just two targeted therapies – Nexavar (sorafenib) and Stivarga (regorafenib) – which provide...

Partnership aimed at the development of molecular diagnostic assays on Biocartis' fully automated Idylla(TM) platform   London (UK) / Mechelen (Belgium), 7 June 2017 ...

Cold chain packaging leader shares knowledge and insight on supply chain compliance at key clinical trial supply event Peli BioThermal, the global name in cold chain,...

Porto, Portugal | Hatfield, UK | – Bial and Eisai today announce that the European Medicines Agency (EMA) has approved Zebinix® (eslicarbazepine acetate) for use as a...